Spire Healthcare Group (LON:SPI) Releases Earnings Results

Key Points

• Spire Healthcare Group reported earnings of GBX 4.10 ($0.05) per share for the quarter, with a net margin of 1.96% and return on equity of 3.82%.
• Following the earnings announcement, shares declined by 2.1%, trading at GBX 213.50 ($2.82) on Friday.
• Berenberg Bank has set a new price target of GBX 280 ($3.70) on the stock, maintaining a "buy" rating.

Spire Healthcare Group (LON:SPI - Get Free Report) announced its earnings results on Thursday. The company reported GBX 4.10 ($0.05) earnings per share for the quarter, Digital Look Earnings reports. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%.

Spire Healthcare Group Stock Down 3.2%

SPI traded down GBX 7 ($0.09) during midday trading on Friday, reaching GBX 211 ($2.80). 867,901 shares of the company were exchanged, compared to its average volume of 1,358,704. The company has a debt-to-equity ratio of 62.25, a quick ratio of 0.74 and a current ratio of 0.70. The company's fifty day moving average price is GBX 215.36 and its 200 day moving average price is GBX 206.63. The company has a market cap of £847.31 million, a price-to-earnings ratio of 30.03, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96. Spire Healthcare Group has a one year low of GBX 168.20 ($2.23) and a one year high of GBX 260.50 ($3.46).

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank reissued a "buy" rating and set a GBX 280 ($3.72) price objective on shares of Spire Healthcare Group in a report on Thursday.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.